SEC Comment Letter 0000000000-25-002409 to Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc.
Date: March 4, 2025 · CIK: 0001636282 · Accession: 0000000000-25-002409
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285341
Letter
March 4, 2025 Heidy King-Jones Chief Legal Officer and Corporate Secretary Spyre Therapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02453 Re:Spyre Therapeutics, Inc. Registration Statement on Form S-3 Filed February 27, 2025 File No. 333-285341 Dear Heidy King-Jones: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Branden C. Berns, Esq.
Show Raw Text
March 4, 2025
Heidy King-Jones
Chief Legal Officer and Corporate Secretary
Spyre Therapeutics, Inc.
221 Crescent Street
Building 23, Suite 105
Waltham, MA 02453
Re:Spyre Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 27, 2025
File No. 333-285341
Dear Heidy King-Jones:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Branden C. Berns, Esq.